Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.55% | 13.56% | 20.22% | 20.63% | 26.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.55% | 13.56% | 20.22% | 20.63% | 26.77% |
| Cost of Revenue | 11.25% | 10.32% | 10.95% | 12.08% | 8.28% |
| Gross Profit | 11.50% | 0.11% | 13.20% | 8.24% | 29.07% |
| SG&A Expenses | 3.66% | 5.37% | 8.58% | 8.41% | 8.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.96% | 8.84% | 10.25% | 10.99% | 8.28% |
| Operating Income | 1.41% | -3.41% | 0.15% | -1.58% | 7.94% |
| Income Before Tax | -9.85% | -10.69% | -0.75% | -2.72% | 9.68% |
| Income Tax Expenses | 39.30% | 47.07% | 87.15% | 256.14% | 254.51% |
| Earnings from Continuing Operations | -10.00% | -10.86% | -1.05% | -3.69% | 8.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.00% | -10.86% | -1.05% | -3.69% | 8.96% |
| EBIT | 1.41% | -3.41% | 0.15% | -1.58% | 7.94% |
| EBITDA | 0.90% | -4.04% | 0.04% | -1.40% | 9.06% |
| EPS Basic | -5.63% | -3.80% | 7.97% | 8.14% | 24.21% |
| Normalized Basic EPS | -0.04% | 0.69% | 8.23% | 9.40% | 24.80% |
| EPS Diluted | -5.63% | -3.80% | 7.97% | 8.14% | 24.21% |
| Normalized Diluted EPS | -0.04% | 0.69% | 8.23% | 9.40% | 24.80% |
| Average Basic Shares Outstanding | 4.20% | 6.61% | 8.96% | 12.31% | 19.26% |
| Average Diluted Shares Outstanding | 4.20% | 6.61% | 8.96% | 12.31% | 19.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |